Free Trial
OTCMKTS:ANTH

Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Anthera Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 05/9/2025 02:21 PM Eastern

About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
$0.0002
Volume
1,662 shs
Average Volume
14,474 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Receive ANTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANTH Stock News Headlines

ANTH Anthera Pharmaceuticals, Inc.
MACK - Merrimack Pharmaceuticals, Inc.
Warning echoes from the Great Depression
This is an urgent warning for All American investors … The current economic chaos is just a preview … What's coming next could be way scarier. In fact, in a matter of days, we could see a radical shift in the stock market … Companies who've been flying high could come crashing to Earth.
See More Headlines

ANTH Stock Analysis - Frequently Asked Questions

Anthera Pharmaceuticals' stock was trading at $0.0001 on January 1st, 2025. Since then, ANTH shares have increased by 0.0% and is now trading at $0.0001.
View the best growth stocks for 2025 here
.

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) posted its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09.

Anthera Pharmaceuticals's stock reverse split on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
3/05/2018
Today
5/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ANTH
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.92
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:ANTH) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners